drugset / Trial / NCT06903065
A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and activity of RO7790121 in participants with advanced metabolic dysfunction-associated steatohepatitis (MASH) fibrosis.
Timeline
- Start
- 2025-04-14
- Primary completion
- 2026-09-24
- Completion
- 2026-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afimkibart | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.